Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study

NCT04680715 is registered in ClinicalTrials.gov with Centre Antoine Lacassagne as lead sponsor.

NCT NCT04680715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study
Lead sponsor
Centre Antoine Lacassagne
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2021
Completion date
June 30, 2028
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

localized breast cancer